Ankush Bhatia
Neurology · Madison, WINPI 1225394802
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,099 of the $7,481 with a category attached, or 81.5%. Nuvation Bio Inc. accounts for 66.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $5,520, more than ten times the $185 reported in 2019.
Across 12 payments — averaging $623.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nuvation Bio Inc.$5K
- AstraZeneca$2K
- Telix Pharmaceuticals$597
- Agios Pharmaceuticals, Inc.$185
- Servier Pharmaceuticals LLC$21
Across 26 payments — averaging $37,534 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$846K
- Jazz Pharmaceuticals Inc.$130K
What the payments were for
- Consulting fees$6,09982%
- Speaking & faculty fees$5007%
- Travel & lodging$4386%
- Food & beverage$4446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nuvation Bio Inc. | 2 | $4,999 |
| AstraZeneca | 5 | $1,680 |
| Telix Pharmaceuticals | 3 | $597 |
| Agios Pharmaceuticals, Inc. | 1 | $185 |
| Servier Pharmaceuticals LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,481 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CotellicCobimetinib Fumarate | 13 | $63,914 |
| Levetiracetam | 33 | $1,548 |
| Dexamethasone | 20 | $748 |
| Lacosamide | 12 | $721 |
| Memantine Hcl | 11 | $436 |
| Ondansetron Hcl | 63 | $353 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 50 | $145 |
| Fluoxetine Hcl | 21 | $78 |
Paid to pharmacies, not to this prescriber.
Other neurology in Madison
- Michael SnyderMadison$284K
- Kelsey GageschMadison$60K
- Brian NagleMadison$25K
- Michael FruchtMadison$22K
- Vanesa BotsfordMadison$11K
- Amanda AbuafMadison$11K
- Christopher LuzzioMadison$9K
- Rama MagantiMadison$6K
- Elizabeth FeltonMadison$5K
- Bhupendra KhatriMilwaukee$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.